Pulmonary Embolism Market Growth Fueled by Rising Cardiopulmonary Cases

The global pulmonary embolism (PE) market is witnessing substantial growth and is projected to expand from an estimated value of US$ 2.3 billion in 2026 to US$ 4.3 billion by 2033, recording a robust compound annual growth rate (CAGR) of 9.5% during the forecast period. This growth is primarily driven by the rising incidence of pulmonary embolism, advancements in diagnostic imaging technologies, and increased adoption of anticoagulants and catheter-based therapies. North America currently leads the market due to advanced healthcare infrastructure and favorable reimbursement policies, while the Asia-Pacific region represents the fastest-growing market, fueled by rising awareness, better diagnostic capabilities, and expanding hospital capacity.

Key Industry Highlights
Medications dominate the pulmonary embolism market, accounting for 68.1% of the global share in 2025. This is largely due to the widespread first-line use of anticoagulants and thrombolytics for low- and intermediate-risk PE cases. These medications are preferred because of their proven clinical efficacy, ease of administration, guideline endorsement, and broad global availability, making them the cornerstone of PE management. Regionally, North America leads with a 38.0% market share, supported by high disease awareness, advanced diagnostic imaging such as computed tomography pulmonary angiography (CTPA), strong reimbursement structures, and early adoption of catheter-based interventions. Asia-Pacific, however, is emerging as the fastest-growing region, driven by improvements in healthcare infrastructure, increasing diagnosis rates, and the adoption of advanced interventional capabilities.

Market Drivers
Several factors are propelling the growth of the pulmonary embolism market. The rising incidence of venous thromboembolism (VTE), an aging population, and increasing prevalence of risk factors such as obesity and cancer are major contributors. Improved diagnostic accuracy, wider adoption of direct oral anticoagulants (DOACs), and the growing popularity of minimally invasive PE treatment approaches further enhance market demand.

Market Opportunities
Significant opportunities exist in the growth of catheter-directed thrombectomy and thrombolysis, the development of safer next-generation anticoagulants, and expansion of pulmonary embolism response teams (PERTs). Additional opportunities are emerging in the development of improved risk-stratification tools and the increasing adoption of PE management in emerging markets, where access to emergency and cardiovascular care is improving.

Market Dynamics

Rising Incidence of Venous Thromboembolism and Aging Population
Pulmonary embolism represents a critical subset of VTE, affecting up to 900,000 individuals annually in the United States and ranking as a leading cause of preventable hospital deaths. According to the CDC, VTE—including deep vein thrombosis (DVT) and PE—causes an estimated 60,000–100,000 deaths per year in the U.S., with sudden death occurring as the first symptom in approximately one-quarter of PE cases. Age is a significant risk factor, with PE incidence rising sharply among older adults. Population-based studies indicate that individuals aged 65–69 experience an annual incidence of approximately 1.3 per 1,000, which increases to around 2.8 per 1,000 among those aged 85–89. The incidence escalates from fewer than 5 per 100,000 in younger adults to over 500 per 100,000 in adults aged 80 and above, driving the demand for early detection, treatment, and long-term management strategies.

High Bleeding Risk Associated with Anticoagulant and Thrombolytic Therapies
While anticoagulants remain the backbone of PE therapy, their use is restricted due to significant bleeding risks. Medications such as warfarin carry an annual bleeding risk of 15–20%, with life-threatening hemorrhages occurring in 1–3% of treated patients. This risk is amplified in older adults and those with renal impairments, which constitutes a substantial portion of the PE patient population. Similarly, thrombolytic therapies used for high-risk or hemodynamically unstable PE patients are associated with major bleeding rates of up to 20% and intracranial hemorrhage risks of 2–3%, limiting their widespread use and prompting the need for safer therapeutic alternatives.

Rapid Growth of Catheter-Directed Thrombectomy and Thrombolysis
Catheter-based and mechanical interventions are increasingly recognized as effective alternatives to systemic thrombolysis, offering reduced clot burden while minimizing hemorrhagic risk. Catheter-directed thrombolysis (CDT) and aspiration thrombectomy are being adopted for intermediate- and high-risk PE patients, where systemic therapy poses a significant bleeding risk. Meta-analyses demonstrate that these interventions improve hemodynamic outcomes and mortality rates while maintaining acceptable safety profiles. Procedural complication rates for catheter-based interventions are reported between 1.4% and 6.7%, markedly lower than systemic thrombolysis, and large-bore mechanical thrombectomy registries show reduced rates of clinical deterioration and hospital readmission. As these techniques gain guideline support and improved outcomes, they are expected to expand the PE treatment landscape beyond conventional anticoagulation.

Category-Wise Analysis

Treatment Segment: Medications Dominate
Medications accounted for 68.1% of the global PE market in 2025. Anticoagulants remain the standard of care, significantly reducing mortality and recurrent VTE. Direct oral anticoagulants such as apixaban and rivaroxaban have shown comparable efficacy to warfarin with lower major bleeding risks, driving their widespread adoption in clinical practice. Approximately 80% of non-massive PE cases are managed with anticoagulants, facilitated by their predictable pharmacokinetics, convenience, and the ability to administer therapy in outpatient settings.

Diagnosis Segment: CT Scan Leads
Computed Tomography Pulmonary Angiography (CTPA) dominates PE diagnosis due to its rapid, high-resolution imaging capabilities and widespread availability. With sensitivity and specificity exceeding 95% for central and segmental emboli, CTPA outperforms older diagnostic methods like ventilation/perfusion scans. Its ability to detect alternative diagnoses such as pneumonia or aortic dissection further enhances its clinical value. The accessibility of multi-detector CT scanners in emergency settings has made CTPA the preferred diagnostic tool, ensuring prompt and accurate PE diagnosis.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/pulmonary-embolism-market.asp

Regional Insights

North America
North America holds a 38.0% share of the global pulmonary embolism market in 2025. The high disease burden, advanced healthcare infrastructure, and availability of advanced diagnostics and treatments such as DOACs and catheter-based interventions contribute to market leadership. Comprehensive reimbursement systems and extensive public health initiatives further facilitate early diagnosis and effective management of PE cases.

Europe
Europe represents a major market due to its large population, well-established healthcare systems, and harmonized clinical guidelines. With over 2.8 million PE cases reported annually, standardized treatment protocols and widespread use of diagnostic imaging such as CTPA and Doppler ultrasound support effective clinical management. Aging demographics and rising cardiovascular risk factors contribute to substantial demand for PE diagnostics and therapeutics.

Asia-Pacific
The Asia-Pacific region is the fastest-growing market due to expanding healthcare infrastructure, increased disease awareness, and better access to diagnostics and treatments. Countries such as China, India, Japan, and South Korea report a high incidence of PE, driven by population size and increasing prevalence of cardiovascular diseases. Rapid adoption of CTPA, interventional labs, and catheter-directed therapies, alongside healthcare reforms and increased funding, are accelerating market growth in the region.

Competitive Landscape
The pulmonary embolism market is moderately competitive, with key players including pharmaceutical companies offering anticoagulants and thrombolytics, and device manufacturers producing catheter-directed thrombectomy systems. Competition is driven by clinical efficacy, safety, technological innovation, and adoption of minimally invasive interventions.

Recent Industry Developments
In February 2026, Bristol Myers Squibb and Johnson & Johnson launched an educational initiative, “Change the Target. Change What’s Possible,” aimed at addressing unmet needs in thromboembolic care. The program focuses on factor XIa inhibition to prevent dangerous clots while preserving normal coagulation. In January 2025, Bayer’s investigational antibody BAY-3018250 entered Phase II trials targeting alpha-2 antiplasmin to enhance clot breakdown, representing a novel mechanism compared with traditional anticoagulants.

Key Players
Major companies in the pulmonary embolism market include Bayer AG, Johnson & Johnson, Boehringer Ingelheim, Pfizer Inc., Bristol-Myers Squibb, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Eli Lilly and Co., Gilead Sciences Inc., Medtronic Plc, Inari Medical Inc., Novartis AG, Sanofi, Viatris Inc., and Takeda Pharmaceutical Co. Ltd.

Conclusion
The global pulmonary embolism market is poised for sustained growth, driven by rising incidence rates, improved diagnostics, expanding use of anticoagulants, and the adoption of minimally invasive catheter-based therapies. North America leads in market share due to advanced infrastructure, while Asia-Pacific shows the highest growth potential. Key opportunities lie in catheter-directed interventions, next-generation anticoagulants, and the establishment of specialized PE response teams. As the market evolves, continued innovation in safer and more effective therapies is expected to drive adoption and improve patient outcomes worldwide.